Articles related to Psychiatry

The FDA has approved once-monthly subcutaneous olanzapine for adults with schizophrenia, supported by placebo-controlled trial data showing symptom improvement and sustained efficacy through 48 weeks, while eliminating several logistical requirements associated with treatment initiation.

Cannabis use at psychiatric admission was associated with a higher risk of early rehospitalization among young adults hospitalized for bipolar or psychotic disorders, although the association weakened over time and was no longer statistically significant by six months.

In an adaptive randomized trial of adults with long COVID, fluvoxamine modestly reduced fatigue and improved quality-of-life scores through 90 days, while metformin findings remained inconclusive after dose modification and early termination.

Interviews with older adults living with dementia or mild cognitive impairment highlighted recurring communication gaps surrounding driving cessation, suggesting that earlier, structured discussions and transition planning may better support patients and families during a highly personal decision.

Growing evidence suggests that exposure to natural environments may improve mood, attention, and selected cognitive functions, although the current literature remains insufficient to establish nature-based interventions as validated treatments for psychiatric disorders.

A systematic review of 12 studies found that vortioxetine consistently improved depressive symptoms in adults aged 65 years and older with major depressive disorder, but evidence for cognitive benefits remained mixed and largely confined to selected cognitive domains.